Sanifit and Mitelos have successfully concluded the development, registration and industrial scaled up of SNF671, a breakthrough patent protected dietary supplement to prevent osteoporosis within postmenopausal women, which was originated at the Laboratory of Renal Lithiasis Research of the University of the Balearic Islands.
SNF671 has proven efficacy both in in vitro and in vivo models, as well as in 3 epidemiology clinical studies, where the exposure to SNF671 correlates with increased bone mineral density and reduced bone mass loss.
SNF671 is of special relevance after the publication in a recent editorial in the British Medical Journal that there is no clinical trial evidence that increasing calcium intake from dietary sources prevents fractures. Quite to the contrary, patients will not benefit from increasing their intake of calcium and will be exposed instead to a higher risk of adverse events such as constipation, cardiovascular events, kidney stones, or admission for acute gastrointestinal symptoms.
Therefore, SNF671 is a new alternative to calcium supplements that comes at the right time, when such supplements are being questioned.
Sanifit and Mitelos are actively seeking licensees and some agreements are in advanced stage of negotiation.